Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc. (ENDV) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ENDV · as of Jun 30, 2025
Ownership Breakdown
1
Institutional Holders
▲ 1 vs Q1
$3
Total Inst. Value
▲ $3 vs Q1
318.75M
Shares Outstanding
freeFloat 75.30%
20,228
13F Shares Held
▲ 20,228 vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ENDV largest shareholders · institutional ownership
Q2 2025 · SEC 13F
Showing top 1 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
HILLTOP PARTNERS LLC pharmaceutical preparations | 20.2K | 0.18% | 0.18% | $3,000 | Aug 25, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2025 vs prior quarter
Q2 2025
0
Increased
+0 shares1
New Positions
first time holders0
Decreased
−0 shares0
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
+1
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ENDV insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Collier Alan Brian CEO | Jul 1, 2020 | Purchase | 100 | $0.10 | $10.24 | 26.2K | Form 4 ↗ |
Collier Alan Brian CEO | Jul 1, 2020 | Purchase | 100 | $0.10 | $10.04 | 26.1K | Form 4 ↗ |
Collier Alan Brian CEO | Jun 30, 2020 | Purchase | 200 | $0.10 | $20.7 | 26.0K | Form 4 ↗ |
Collier Alan Brian director | Feb 22, 2020 | Purchase | 100 | $0.96 | $96.49 | 25.8K | Form 4 ↗ |
Collier Alan Brian CEO | Jan 2, 2020 | Purchase | 100 | $1.75 | $175 | 25.7K | Form 4 ↗ |
Collier Alan Brian CEO | Dec 30, 2019 | Purchase | 100 | $2.25 | $225 | 25.6K | Form 4 ↗ |
Collier Alan Brian CEO | Dec 16, 2019 | Purchase | 500 | $0.00 | $0.75 | 25.42M | Form 4 ↗ |
Collier Alan Brian CEO | Dec 12, 2019 | Purchase | 1,000 | $0.00 | $2.2 | 25.42M | Form 4 ↗ |
Collier Alan Brian CEO | Dec 11, 2019 | Purchase | 100 | $0.00 | $0.19 | 25.42M | Form 4 ↗ |
Collier Alan Brian CEO | Dec 11, 2019 | Purchase | 1,000 | $0.00 | $2 | 25.42M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Endonovo Therapeutics, Inc. (ENDV) is primarily owned by institutional investors, who hold approximately 0.0% of total shares outstanding. Company insiders own approximately 24.70%, while retail and public investors account for the remaining 75.29%.
The largest institutional shareholder of Endonovo Therapeutics, Inc. is HILLTOP PARTNERS LLC, holding approximately 20,228 shares — equal to 0.18% of outstanding shares — as of June 30, 2025.
A total of 1 institutional investors currently hold ENDV stock, with a combined institutional value of approximately $3 as of the most recent 13F filing period.
Frequently asked questions
ENDV ownershipEndonovo Therapeutics, Inc. (ENDV) is primarily owned by institutional investors, who hold approximately 0.0% of shares. The largest shareholder is HILLTOP PARTNERS LLC with a 0.18% stake. Company insiders hold 24.70%. Data sourced from SEC Form 13F as of June 30, 2025.